The road ahead for medical affairs and MSL teams – Interview with Dr David Grolman

Medical News: The COVID-19 disruption has created an opportunity for pharmaceutical companies to revisit how they engage with customers, including the chance to take a fresh look at how their Medical Affairs teams communicate with increasingly important stakeholders.

Overnight, an industry so reliant on face-to-face engagement found itself
extremely limited in its ability to engage with customers in person.

In an interview with Health Industry Hub, Dr David Grolman, explored the internal and external impacts of the pandemic on medical affairs and medical science liaison (MSL) teams and the road ahead in reimagining an enhanced scientific engagement with clinicians post-2020.

Dr Grolman is the Medical Director of the Hospital Business Unit and Medical Affairs Cluster Lead of International Developed Markets at Pfizer Australia, New Zealand & Korea. He is also a past President and current Executive Secretary of the Australian Pharmaceutical Medical and Scientific Professionals Association (APPA).

Key Discussions Points

1. Key internal impacts of COVID-19 on medical affairs and MSL teams in 2020
2. Virtual engagement experience of Australian MSLs and medical affairs teams with KOLs and its evolution in 2021
3. The changing face of congresses and social media interactions
4. Reimagining an enhanced scientific engagement moving forward
5. Shift in the way commercial and medical teams of the future will engage with clinicians to meet the changing stakeholder needs.